

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 November 2018 (29.11.2018)



(10) International Publication Number
WO 2018/215801 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 403/14 (2006.01)
C07D 401/12 (2006.01) C07D 409/14 (2006.01)
C07D 403/12 (2006.01) C07D 417/14 (2006.01)
C07D 413/14 (2006.01) A61K 31/4184 (2006.01)

Therapeutics, The Institute of Cancer Research, London SM2 5NG (GB).

(21) International Application Number:

PCT/GB2018/051447

(22) International Filing Date:

25 May 2018 (25.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1708502.8 26 May 2017 (26.05.2017) GB
1806130.9 13 April 2018 (13.04.2018) GB

(71) Applicant: **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; Angel Building, 407 St John Street, London EC1V 4AD (GB).

(72) Inventors: **BELLENIE, Benjamin Richard**; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG (GB). **CARTER, Michael Keith**; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG (GB). **CHEUNG, Kwai Ming Jack**; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG (GB). **DAVIS, Owen Alexander**; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG (GB). **HOELDER, Swen**; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG (GB). **LLOYD, Matthew Garth**; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG (GB). **VARELA RODRÍGUEZ, Ana**; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer

(74) Agent: **HGF LIMITED**; 4th Floor, Merchant Exchange, 17-19 Whitworth Street West, Manchester Greater Manchester M1 5WG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6



Formula I

(57) Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X₁, X₂, R¹, R² and R³ are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.



WO 2018/215801 A1